After earning a bachelor’s degree in information technology from Hodges University, Ray Blanco spent over a decade working for public and private companies as a network technician and systems analyst. Ray used to work for one of the most successful private wealth management firms in the country — with over $30 billion in assets under management — to design and oversee their entire network infrastructure, everything from Internet connectivity to data integrity and security. This experience included technology management for large trading and investment firms. From advanced robotics and avionics… to genomics and biotechnology… Ray is an expert. Combining his passion for technology with his financial and stock market expertise, he joined the team in 2009. He is the editor of Technology Profits Confidential, FDA Trader, Penny Pot Profits and Breakthrough Technology Alert and is the lead contributor to Technology Profits Daily.
I have some great news from our biotechnology companies for you today. First, however, I'd like to let Patrick Cox tell you about something taking place in biotech that's a little bit closer to home. If you recall, Patrick and I toured BioTime's headquarters and labs in April, and he volunteered to have his skin cells used to demonstrate BioTime's revolutionary regenerative medical platform.
Several of our portfolio picks have reported earnings over the last few days. Unfortunately, the weakening global economy is holding back earnings for many technology companies. I remain confident that the long-term tech trends our companies drive will help them weather the current environment. It also appears that share price moves after earnings announcements are being driven less on earnings themselves than on beating expectations and guidance. You can almost hear a collective sigh of relief when a tech company meets or beats.
Nvidia’s (NASDAQ:NVDA) diversification into mobile computing technology is beginning to pay off. As you know, the company has long been the leader in graphical computing technology. The company, however, has also moved aggressively into mobile computing. It recently flexed its technology muscles when it launched Tegra 3, the world’s first quad-core mobile processor. Based on...
I had a wonderful time meeting many of you in Vancouver last week. I enjoyed spending time with attendees from past years, as well as making some new friends. Now that I'm back, I'd like to update you on some of our biotech recommendations. Following on U.S. regulatory approval earlier this year, Vertex (NASDAQ: VRTX) just received approval in Europe for Kalydeco. By correcting for defective proteins regulating the transport of ions across cellular membranes, Kalydeco is the first-ever available cystic fibrosis therapy attacking the roots of the disease.
If you recall, we added NXP Semiconductors to our portfolio earlier this year, based partly on the promise of an emerging technology called near-field communication (NFC). By creating a wireless link capable of quickly handling transactions using a mobile device, NFC technology will change the way we pay.
With doom and gloom headlines dominating the financial news, what should investors be doing? Is the sky truly falling? Is it the end of the world as we know it? Is it time to head for the hills? At this year's Agora Financial Investment Symposium, we'll be hearing the expert opinions of leading international speakers. As in past years, Patrick Cox has prepared a thought-provoking and contrarian presentation in his signature style. What follows is a sneak preview.
“There are two consequences in history; an immediate one, which is instantly recognized, and one in the distance, which is not at first perceived.” -- Frederic Bastiat The weather has finally settled down around here. Tropical Storm Debby treated us to rain for days on end. Strong winds and pounding rains have reduced my tomato and pepper patch to tatters. Internet connectivity has been hit or miss, but thankfully, it's all over now, although some areas further north are still waiting on floodwaters to recede. This morning, the big news was the Supreme Court's ruling upholding Obamacare. Stocks, already down for the day, plummeted further on the news. Emerging biotechnology companies appear to be among the hardest hit.
Patrick Cox and I spent the better part of Wednesday afternoon visiting Teva's chairman, Dr. Phillip Frost, at his Miami office. Dr. Frost became vice chairman of Teva upon its acquisition of Miami pharmaceutical company Ivax Corp., which he sold to Teva in 2006 for over $7 billion. He became chairman in 2010, and was re-elected to the position last month. This personal visit was, to put it mildly, a wonderful opportunity to learn what is on the mind of one of the pharmaceutical industry's great investors and leaders.
Last week, several of the cancer warriors in our portfolio presented new data on the power of their molecular wares at ASCO. Seattle Genetics (NASDAQ:SGEN) just followed up on its own presentation this week with new data for Adcetris, its lead compound. Aimed at cancer that expresses a target called CD30, Adcetris received approval from the FDA for late-stage lymphoma last year. The new data are for Adcetris used to treat relapsed or resistant Hodgkin's lymphoma in patients who have received stem cell transplants. Seventy-five percent of patients showed a positive response to therapy, while a full third showed their condition completely clearing up.
This week, the big news in biotechnology was the annual ASCO meeting. No, ASCO isn't a stock ticker symbol. It is an acronym for the American Society of Clinical Oncology, which hosted the biggest cancer research event of the year this week. Several of our biotechnology companies presented new clinical data at this year's event. I am pleased to say there is a lot of good portfolio news to update you on. Along with Seattle Genetics, ImmunoGen's platform is a revolutionary new technology that links engineered antibodies to toxic payloads. When the antibody is designed to target a molecule carried by cancer cells, it penetrates the cell. Once inside, the toxin – a very powerful chemotherapy compound – is released to kill the cell. The advantage of this approach is that unlike traditional chemotherapy, the damage to healthy cells is reduced or eliminated.